Showing results (101-110 of 389) with videos related to

Sort By:
Pageof 39
Oncology and Therapy|February 24, 2021
Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in ArgentinaVictoria Wurcel, Emilie Scherrer, Raquel Aguiar-Ibanez, et al.
Oncology and Therapy|November 3, 2021
Implementing a Standardized Care Pathway Integrating Oncology, Palliative Care and Community Care in a Rural Region of Mid-NorwayAnne-Tove Brenne, Erik Torbjørn Løhre, Anne Kari Knudsen, et al.
Oncology and Therapy|March 7, 2017
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future ProspectsAvineesh Singh, Vijay K Patel, Deepak K Jain, et al.
Oncology and Therapy|March 7, 2017
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal CancerLourens T Bloem, Richard De Abreu Lourenço, Melvin Chin, et al.
Oncology and Therapy|March 7, 2017
Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United StatesRita Caldeira, Mark Scazafave
Oncology and Therapy|March 7, 2017
Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 CasesMarion Wobser, Theresa Reinartz, Sabine Roth, et al.
Oncology and Therapy|March 7, 2017
A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell ModelsWafaa Hassan, Kenny Chitcholtan, Peter Sykes, et al.
Oncology and Therapy|March 7, 2017
Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in MalaysiaNajlaa Maddin, Azlan Husin, Siew Hua Gan, et al.
Oncology and Therapy|January 5, 2025
Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic ReviewCesare Piazza, Claudia Montenegro, Michele Tomasoni, et al.
Oncology and Therapy|April 7, 2025
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in SpainCristina Encinas, Virginia Lozano, Patrick Hlavacek, et al.
Pageof 39